Expert Perspectives & Insights into CAR T-cell Therapy in Relapsed / Refractory Acute Lymphoblastic Leukemia - Episode 19
Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting
Key opinion leaders address the availability of brexucabtagene autoleucel (brexu-cel) at their institutions and outline procedures for ensuring risk evaluation and mitigation strategy compliance and comprehensive training across multidisciplinary teams.
Video Player is loading.
Video content above is prompted by the following:
- For those who have brexu-cel on-formulary or available at your institution, what processes did you and your team take to ensure REMS compliance and training among multidisciplinary team members?
- Typically, is a physician, pharmacist, nurse, quality coordinator or another member of the team the REMS Authorized Representative?
- At your institution, are patients receiving CAR-T cell Therapy in the outpatient or inpatient setting?
- For those infusing CAR-T cell Therapy in the outpatient setting, how are patients being monitored?